Chemotherapy-induced transverse melanonychia

Ng, Chen Fei; Tan, Hui Jan; Remli, Rabani

doi:10.1136/bcr-2021-245878

Cited by 2 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While there can be multiple causes of longitudinal melanonychia like drugs or systemic illnesses, only a few causes of transverse melanonychia have been reported. Chemotherapeutic agents including doxorubicin, bleomycin, pemetrexed, dacarbazine, imatinib and hydroxyurea, low dose radiation, electron beam therapy, PUVA therapy, infliximab, melanotan, antimalarials, zidovudine have all been reported to cause transverse melanonychia [2][3][4][5][6][7].…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, drug deposition within the nail plate itself can contribute to nail pigmentation leading to diffuse melanonychia. When the melanocyte activation occurs throughout the matrix, it may lead to either diffuse or transverse melanonychia, depending on where the melanocyte activation is sustained or transient, respectively, whereas focal melanocyte activation leads to longitudinal melanonychia [2][3][4][5][6][7][8][9]. Onychoscopy features are suggestive of melanocyte activation, including pale bands of homogeneous greyish background pigmentation with regular grey lines [9].…”

Section: Discussionmentioning

confidence: 99%

“…It is a rare nail alteration that can occur as a side-effect of certain medications, in addition to other diseases like thyroid disorders and iron deficiency. While there are no documented reports of nail changes specifically associated with dasatinib, a tyrosine kinase inhibitor, used for the treatment of Philadelphia chromosome-positive chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia, we present a case of transverse melanonychia possibly related to dasatinib therapy [1, 2].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Dasatinib-Induced Transverse Melanonychia

Tyagi,

Gaurav,

Kaur

2023

Skin Appendage Disord

View full text Add to dashboard Cite

Introduction: Transverse melanonychia, characterized by grey to black pigmented bands traversing the nail plate, can occur as a side-effect of certain medications. While no documented reports specifically associate dasatinib, a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia, with nail changes, we present a case of transverse melanonychia possibly related to dasatinib therapy. Case Report: A 54-year-old male with CML, receiving dasatinib for 1.5 years, presented with transverse pigmented lines involving all fingernails and toenails. Clinical examination revealed discrete bands of transverse melanonychia in the nails. Onychoscopy of all finger- and toenails revealed multiple longitudinal grey lines within transverse grey bands of homogeneous chromonychia. Based on clinical presentation, onychoscopic features, and temporal association with dasatinib therapy, a provisional diagnosis of dasatinib-induced transverse melanonychia was made. Discussion: The exact mechanisms underlying melanonychia are not fully understood but may involve nail matrix or toxicity, stimulation of nail-matrix melanocytes, or drug deposition within the nail plate. This case highlights the possibility of dasatinib-induced transverse melanonychia and underscores the importance of monitoring and evaluating nail changes in patients undergoing dasatinib treatment.

show abstract